US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dermata Therapeutics, Inc.

0.0200

0.0000

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:0.0200

Open:0.0200

Low:0.0200

Close:0.0200

Loading ...

Overview Company News Filings

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

ACCESS Newswire

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

ACCESS Newswire

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

ACCESS Newswire

Dermata to Present on BioPub on January 31, 2025

ACCESS Newswire

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

ACCESS Newswire

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DRMAW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DRMAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DRMAW\",,,,,undefined,":{"symbol":"DRMAW","market":"US","secType":"STK","nameCN":"Dermata Therapeutics, Inc.","latestPrice":0.02,"timestamp":1754510400000,"preClose":0.02,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-06 16:00:00 EDT","open":0.02,"high":0.02,"low":0.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754553600000},"marketStatusCode":0,"adr":0,"listingDate":1628827200000,"exchange":"NASDAQ","adjPreClose":0.02,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DRMAW\",,,,,undefined,":{"symbol":"DRMAW","floatShares":0,"roa":"-95.90%","roe":"-206.26%","lyrEps":0,"shares":0,"dividePrice":0,"high":0.02,"amplitude":0,"preClose":0.02,"low":0.02,"week52Low":0.0052,"pbRate":"0.00","week52High":0.044,"institutionHeld":0,"latestPrice":0.02,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0.02,"prevYearClose":0.0107,"prevWeekClose":0.02,"prevMonthClose":0.02,"prevQuarterClose":0.0177,"fiveDayClose":0.0199,"twentyDayClose":0.0166,"sixtyDayClose":0.0249},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DRMAW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522557710","title":"Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2522557710","media":"ACCESS Newswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522557710?lang=en_us&edition=fundamental","pubTime":"2025-03-28 08:15","pubTimestamp":1743120900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc.  , a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the Company's common stock, having exercise prices of $1.58 and $4.91 per share, issued by Dermata in September 2024  and May 2024 , at a reduced exercise price of $1.284 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 . The closing of the offering is expected to occur on or about March 28, 2025, subject to satisfaction of customary closing conditions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-therapeutics-announces-exercise-warrants-001500364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4112","TSYW.SI","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","USAW.SI","LU2210149790.SGD","QLD","TQQQ","IE00BKPKM429.USD","QID","BK4539","NVIW.SI","PSQ","IE00B64PRP62.GBP","DRMA",".IXIC","BK4007","MNQmain","NDAQ","NQmain","BK4139","USJW.SI","IE00B3QW5Z07.USD","SQQQ","LU2095319765.USD","BK4588","DRMAW","LENZ"],"gpt_icon":1},{"id":"2520689766","title":"Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520689766","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520689766?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:16","pubTimestamp":1742242560,"startTime":"0","endTime":"0","summary":"- Dermata expects to announce topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research  clinical trial by end of March 2025 -. - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics  to study DMT410 for the treatment of axillary hyperhidrosis -- Raised $2.55 million in gross proceeds from a private placement financing in January 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and certain members of the Company's board of directors -. SAN DIEGO, CA / ACCESS Newswire / March 17, 2025 / Dermata Therapeutics, Inc.  , a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today highlighted recent corporate progress and reported financial results for the year ended December 31, 2024.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-therapeutics-provides-corporate-reports-201600200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","DRMAW","DRMA","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2516764726","title":"Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2516764726","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516764726?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:03","pubTimestamp":1741093380,"startTime":"0","endTime":"0","summary":"- STAR-1 topline results expected by the end of March 2025 -. - Over 30 million acne patients seek treatment in the U.S. each year -. - XYNGARI Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S. and Latin America -. The XYNGARI Phase 3 STAR-1 clinical study will evaluate the efficacy, safety, and tolerability of XYNGARI in patients with moderate-to-severe facial acne. The STAR-1 study was a randomized (2:1), double-blind, and placebo-controlled study enrolling 520 patients with moderate-to-severe acne, ages 9 years and older in the United States and Latin America. The primary endpoints include the mean change from baseline in inflammatory and noninflammatory lesion counts and the Investigator Global Assessment  treatment response. IGA is measured on a 5-point scale (0-4), with a treatment response defined as at least a 2-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/dermata-announces-last-patient-completes-130300327.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-announces-last-patient-completes-130300327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4007","DRMAW","IGA","DRMA","BK4139"],"gpt_icon":0},{"id":"2514099038","title":"Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099038","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099038?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:58","pubTimestamp":1740488280,"startTime":"0","endTime":"0","summary":"- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -. - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis -. DMT410 is the Company's combination treatment regimen that uses the unique mechanical features of the Company's XYNGARI product candidate to facilitate the intradermal delivery of botulinum toxin by topical application rather than through multiple injections with a needle. The treatment consists of an initial topical application of XYNGARI to the treatment area where the microscopic spicules penetrate the stratum corneum to create microchannels into the dermis allowing for the topical application and penetration of botulinum toxin. The Company has successfully completed proof-of-concept Phase 1 clinical trials using DMT410 in combination with BOTOX for the treatment of primary axillary ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-receives-notice-acceptance-australian-125800885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4007","BK4539","DRMA","DRMAW"],"gpt_icon":0},{"id":"2507666591","title":"Dermata to Present on BioPub on January 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507666591","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507666591?lang=en_us&edition=fundamental","pubTime":"2025-01-30 05:05","pubTimestamp":1738184700,"startTime":"0","endTime":"0","summary":"- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community -. SAN DIEGO, CA / ACCESS Newswire / January 29, 2025 / Dermata Therapeutics, Inc.  , a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced it will be featured as the presenting company on BioPub on January 31, 2025, at 12:00PM ET.This live, interactive, online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Gerry Proehl, and Chief Development Officer, Chris Nardo, Ph.D., in real time. Mr. Proehl and Dr. Nardo will provide an update of the Company's progress on their ongoing XYNGARI STAR-1 Phase 3 clinical trial, which has topline results expected in March 2025, discuss the recent collaboration agreement signed with Revance Therapeutics, and answer audience questions.Event: BioPub","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-present-biopub-january-31-210500764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","DRMAW","BK4539","DRMA","BK4139"],"gpt_icon":0},{"id":"2505747885","title":"Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2505747885","media":"ACCESS Newswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505747885?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc.  , a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,007,880 shares of common stock  and accompanying warrants to purchase up to 2,007,880 shares of common stock at a purchase price of $1.27 per share of common stock  and accompanying warrant in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The warrants will have an exercise price of $1.27 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants and will expire five years from the effective date of stockholder approval. The closing of the offering is expected to occur on or about January 23, 2025, subject to the satisfaction of customary closing cond","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-therapeutics-announces-2-55-130000738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4539","LU2210150020.SGD","DRMAW","LENZ","IE00BGHQF748.EUR","BK4007","IE00BKPKM429.USD","BK4112","NDAQ","DRMA","IE00B64PRP62.GBP","LU2095319765.USD","BK4585","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD",".IXIC"],"gpt_icon":0},{"id":"2505278019","title":"Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505278019","media":"ACCESS Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505278019?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:00","pubTimestamp":1737464400,"startTime":"0","endTime":"0","summary":"The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari with Daxxify to treat primary axillary hyperhidrosis -. If successful, the Companies may explore clinical development in additional indications -. Xyngari with Daxxify has the potential to be the first approved needle-free intradermal delivery of a botulinum toxin product -. \"Revance is excited to partner with Dermata to jointly explore the potential for Daxxify and Xyngari for the needle-free treatment of axillary hyperhidrosis and to expand the opportunities for Daxxify beyond injections,\" commented Mark Foley, Chief Executive Officer of Revance.Daxxify has received approval in the United States for specific uses in treating moderate to severe glabellar lines and cerv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-revance-enter-clinical-trial-130000355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","R","BK4007","BK4232","BK4588","BK4099","DRMA","DRMAW","BK4022","BK4555","BK4139","03160","TM","BK4585"],"gpt_icon":0},{"id":"2491694525","title":"Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491694525","media":"ACCESSWIRE","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491694525?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:00","pubTimestamp":1734357600,"startTime":"0","endTime":"0","summary":"- Xyngari  is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 -. SAN DIEGO, CA / ACCESSWIRE / December 16, 2024 / Dermata Therapeutics, Inc.  , a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that it received approval from U.S. Food and Drug Administration  of the proprietary name, Xyngari  , for its Phase 3 clinical drug candidate in acne. The proprietary name, Xyngari, is approved pending the successful submission and acceptance of a new drug application .Xyngari is a novel, once-weekly, topical product candidate derived from a freshwater sponge being developed for the treatment of multiple skin diseases. Xyngari has multiple mechanisms of action that include mechanical components and chem","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-receives-approval-fda-proprietary-140000682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4555","03160","BK4139","BK4539","BK4585","IGA","BK4588","BK4099","BK4007","TM","DRMA","DRMAW"],"gpt_icon":0},{"id":"2490801604","title":"Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2490801604","media":"ACCESSWIRE","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490801604?lang=en_us&edition=fundamental","pubTime":"2024-12-10 22:00","pubTimestamp":1733839200,"startTime":"0","endTime":"0","summary":"- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne -. - Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 study for the treatment of acne and expects to announce topline results in March 2025 -. \"We are thrilled to receive this notice of allowance in the U.S., which we believe further validates DMT310's novel approach to treat acne with a once weekly topical product,\" commented Gerry Proehl, Dermata's Chairman, President, and CEO. \"Given the unique features and benefits of DMT310, we believe, if approved, it could potentially transform the current acne treatment guidelines and allow DMT310 to be a first-line treatment option. We also recently completed enrollment in the first of two DMT310 Phase 3 studies and are eager to announce topline results in March of 2025. We look forward to this allowed patent application eventually advancing to issuance and support our intellectual property protections ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-receives-notice-allowance-u-140000411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DRMAW","DRMA"],"gpt_icon":0},{"id":"2488943475","title":"Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2488943475","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488943475?lang=en_us&edition=fundamental","pubTime":"2024-12-03 22:00","pubTimestamp":1733234400,"startTime":"0","endTime":"0","summary":"- Over 30 million acne patients seek treatment in the U.S. each year -. SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Dermata Therapeutics, Inc.  , a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has successfully completed enrollment in its pivotal Phase 3 Spongilla Treatment for Acne Research  study of DMT310, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The STAR-1 study is the first of two Phase 3 studies that, if positive, would be used by Dermata to support the filing of a new drug application  for DMT310 for the treatment of moderate-to-severe acne.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-completes-enrollment-first-pivotal-140000407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IGA","BK4139","BK4539","BK4007","DRMA","DRMAW"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DRMAW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DRMAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DRMAW\",market:\"US\",delay:false,,,undefined,":{}}}